Literature DB >> 20065020

Molecular basis for agonism in the BB3 receptor: an epitope located on the interface of transmembrane-III, -VI, and -VII.

F Gbahou1, B Holst, T W Schwartz.   

Abstract

Epitopes determining the agonist property of two structurally distinct selective ligands for the human bombesin receptor subtype 3 (BB3), [D-Tyr6,(R)-Apa11,Phe13, Nle14]-bombesin(6-14) (Pep-1) and Ac-Phe-Trp-Ala-His(TauBzl)-Nip-Gly-Arg-NH2 (Pep-2), were mapped through systematic mutagenesis of the main ligand-binding pocket of the receptor. The mutational map for the smaller Pep-2 spanned the entire binding pocket of the BB3 receptor. In contrast, the much fewer mutational hits for the larger Pep-1 were confined to the center of the pocket, i.e., the opposing faces of the extracellular segments of transmembrane (TM)-III, TM-VI, and TM-VII. All the residues, which upon mutation affected Pep-1, were also hits for Pep-2 and included those that were most essential for the function of Pep-2: LeuIII:04 (Leu(123)), TyrVI:16 (Tyr(291)), and ArgVII:06 (Arg(316)). The BB3 receptor was found to signal with 12% ligand-independent activity that was strongly influenced both positively and negatively by several mutations in the binding pocket. The substitutions, which decreased the constitutive signaling, included not only the major mutational hits for the peptide agonists but also mutations more superficially located in the receptor. It is concluded that activation of the BB3 receptor is dependent upon an epitope in the main ligand-binding pocket at the interface between TM-III, TM-VI, and TM-VII that corresponds to the site where, for example, activating metal ion sites have been constructed previously in 7TM receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20065020     DOI: 10.1124/jpet.109.162131

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.

Authors:  Marc L Reitman; Victor Dishy; Allison Moreau; William S Denney; Chengcheng Liu; Walter K Kraft; Alex V Mejia; Mark A Matson; S Aubrey Stoch; John A Wagner; Eseng Lai
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Receptor-specific crosstalk between prostanoid E receptor 3 and bombesin receptor subtype 3.

Authors:  Yan Zhang; Yanfang Liu; Lehao Wu; Chao Fan; Zhiwei Wang; Xiuli Zhang; Amal Alachkar; Xinmiao Liang; Olivier Civelli
Journal:  FASEB J       Date:  2018-01-22       Impact factor: 5.191

Review 3.  Bombesin-Like Receptor 3: Physiology of a Functional Orphan.

Authors:  Cuiying Xiao; Marc L Reitman
Journal:  Trends Endocrinol Metab       Date:  2016-04-04       Impact factor: 12.015

4.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

5.  Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7.

Authors:  Anne Steen; Stefanie Thiele; Dong Guo; Lærke S Hansen; Thomas M Frimurer; Mette M Rosenkilde
Journal:  J Biol Chem       Date:  2013-03-14       Impact factor: 5.157

6.  Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.

Authors:  Terry W Moody; Veronica Sancho; Alessia di Florio; Bernardo Nuche-Berenguer; Samuel Mantey; Robert T Jensen
Journal:  Peptides       Date:  2011-06-25       Impact factor: 3.750

7.  Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors.

Authors:  Paola Moreno; Samuel A Mantey; Bernardo Nuche-Berenguer; Marc L Reitman; Nieves González; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2013-07-26       Impact factor: 4.030

8.  Constitutively active BRS3 is a genuinely orphan GPCR in placental mammals.

Authors:  Huihao Tang; Chuanjun Shu; Haidi Chen; Xiaojing Zhang; Zhuqing Zang; Cheng Deng
Journal:  PLoS Biol       Date:  2019-03-06       Impact factor: 8.029

9.  Search for an Endogenous Bombesin-Like Receptor 3 (BRS-3) Ligand Using Parabiotic Mice.

Authors:  Dalya M Lateef; Cuiying Xiao; Marc L Reitman
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

10.  Bombesin-like receptor 3 (Brs3) expression in glutamatergic, but not GABAergic, neurons is required for regulation of energy metabolism.

Authors:  Cuiying Xiao; Ramón A Piñol; Jesse Lea Carlin; Cuiling Li; Chuxia Deng; Oksana Gavrilova; Marc L Reitman
Journal:  Mol Metab       Date:  2017-09-15       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.